Melanoma cell lysate antigens (MCL)

The strategy involving melanoma cell lysate antigens focuses on stimulating a broad, polyvalent immune response against malignant melanoma. Melanoma cell lysates (MCL) are produced by the mechanical or thermal lysis of whole melanoma cells, releasing a diverse array of tumor-associated antigens (TAAs) and neoantigens [PubMed: 16505415]. These antigens are delivered to antigen-presenting cells (APCs), such as dendritic cells, which internalize and process them into peptides for presentation on Major Histocompatibility Complex (MHC) class I and II molecules [Nature: 392(6673)]. This presentation is essential for the activation and clonal expansion of melanoma-specific cytotoxic T lymphocytes (CTLs) and helper T cells capable of identifying and eliminating tumor cells [Nature Medicine: 4(3)]. By providing a wide spectrum of antigens, this approach aims to reduce the likelihood of tumor escape compared to single-antigen vaccines [Journal of Clinical Oncology: 20(10)]. Although clinically explored through vaccines like Melacine, this entity represents a therapeutic modality or complex antigen source rather than a single molecular target [Vaccines: 3(4)].

Other names

Melanoma cell lysateWhole-cell melanoma lysateMCL antigensPolyvalent melanoma lysateTumor cell lysate

Melanoma cell lysate antigens are captured and processed by antigen-presenting cells (APCs), which then present the resulting peptides on MHC molecules to prime and activate melanoma-specific cytotoxic T lymphocytes (CTLs) for tumor cell lysis.